First-ever combined heart pump & gene-edited pig kidney transplant gives new hope to patient with terminal illness
Surgeons at NYU Langone Health performed the first combined mechanical heart pump and gene-edited pig kidney transplant surgery.
News
Read the latest press releases and news articles about transplantation medicine, innovations in the care of transplant patients and ImmunoFree.
The bone-marrow-transplant revolution
In the fall of 2021, Gabriel Arias felt like his body was “rotting from the inside.” He was diagnosed with acute myeloid leukemia, a form of blood cancer so aggressive that doctors had him hospitalized the day of his biopsy.
Drs. Fuchs and Leventhal Present Important Clinical Immune Tolerance Research at the 6th International Sam Strober Workshop
Drs. Ephraim Fuchs and Joseph Leventhal were among the esteemed speakers at the 6th International Sam Strober Workshop on Clinical Immune Tolerance Research, which was held March 25–26, 2024, at Oxford University’s Exeter College. This year’s event, with a focus on autoimmunity, aimed to expand the dialogue surrounding transplantation tolerance and autoimmune regulation. Drs. Fuchs…
National Kidney Foundation Innovation Fund Invests in ImmunoFree
The National Kidney Foundation (NKF) announced today its latest strategic investment through its NKF Innovation Fund. The fund will support ImmunoFree, a pioneering biomedical company dedicated to reshaping the landscape of organ transplantation by eliminating the need for immunosuppressive medications.
Dr. Ephraim Fuchs Joins ImmunoFree, Inc. as its Chief Medical Officer
Today, ImmunoFree, Inc. announced that Dr. Ephraim Fuchs has been appointed the Chief Medical Officer of ImmunoFree. In his role as CMO, Dr. Fuchs will oversee all medical and scientific affairs of the company and be responsible for the development of the ImmunoFree tolerance protocol for the 1,000,000+ transplant recipients worldwide who can benefit from…
New Study Shows Promise in Enabling Transplant Recipients to Eliminate Immunosuppression Medications
While kidney transplantation has traditionally required recipients to take immunosuppressive drugs for the remainder of their lives to prevent organ rejection, a new study offers hope for a treatment that may enable transplant recipients to take lower dosages of these drugs, or even none at all. The study, published in Clinical Transplantation in August 2023,…
Acquisition of the Talaris Transplant Tolerance Business
The Talaris Therapeutics Transplant Tolerance Business has been acquired by ImmunoFree Inc., a newly formed biotech company backed by the National Kidney Registry. ImmunoFree’s mission is to eliminate the need for lifelong immunosuppressive medications for transplant recipients, enabling them to live longer, healthier lives. (Read the press release.) ImmunoFree will commence a new clinical trial…
ImmunoFree, Inc. has Acquired Talaris Therapeutics, Inc.’s Tolerance Business
ImmunoFree, Inc. announced today that it has acquired all rights to FCR001, a cellular therapy product, and the sponsorship of the FREEDOM-1 Study formerly owned by Talaris Therapeutics (TALS). ImmunoFree has assumed all financial and regulatory responsibilities related to these clinical trials. Effective immediately, ImmunoFree will oversee all remaining close-out activities and the shutdown of…
The National Kidney Registry Reaches 2,000 Active Patient Microsites for Kidney Patients Seeking a Living Donor
Today the National Kidney Registry announced the activation of its 2,000th patient microsite. The microsite program provides free websites and coaching to transplant patients seeking a living donor. The theory behind the microsite program is that if a patient can direct potential donors to a website that effectively tells their story, they will connect with…
Stem cells ease lung transplant rejection
A transfusion of mesenchymal stem cells stabilized and, in some cases, improved transplanted lung function in patients with chronic organ rejection.